Scandinavian biopharma

Lou Bourgeois, Ibrahim Khalil, Shiri Meron-Sudai, Nils Carlin, Nsofwa Sukwa, Tom Wierzba and Jahangir Hossain

5 December 2022 11:31

New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines

At the annual PATH-hosed Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference, diarrhea is always the center of the conversation, and this year's gathering was no exception. During the 2022 VASE Conference in Washington, DC last week more than 300 experts traveled from around the world to learn about the latest enteric vaccine research.

6 Juli 2016 13:34

We are proud!

We are a part of the global movement to defeat diarrheal disease. That makes us proud!

5 Juni 2015 11:03

ETVAX® ”the lead candidate” på CISTM14

”Etvax is the lead candidate in the field of ETEC”. Så sa Richard Walker under programpunkten ”Advances in ETEC and Shigella prevention throught vaccination” på International Society of Travel Medicin konferens, CISTM14, förra veckan.

1 December 2014 14:01

Mapping the spread of diarrheal bacteria supports the design of our new vaccine

Every year hundreds of thousands of people die from diarrhea caused by ETEC bacteria. A study published in Nature Genetics describes how the University of Gothenburg, our collaborators, have mapped the spread of ETEC strains around the world. It provides key information about how pathogenic bacteria arise, which will be important for our vaccine currently under development.

1 December 2014 13:50

Studie av diarrébakteriers spridning stödjer designen av vårt nya vaccin

Varje år dör hundratusentals av diarrésjukdom som orsakats av ETEC-bakterier. I en studie som publiceras i Nature Genetics har vår samarbetspartner, Göteborgs universitet, kartlagt hur ETEC-bakteriens stammar sprids över världen. Studien ger viktig kunskap om hur sjukdomsframkallande bakterier uppstår vilket har betydelse för vårt diarrévaccin som är under utveckling.

23 December 2013 09:28

Scandinavian Biopharma and PATH sign collaborative development agreement after successful Phase I study of a novel vaccine candidate against diarrheal disease.

The international global health nonprofit organization PATH and Scandinavian Biopharma have agreed to continue their collaboration to develop a novel vaccine candidate against diarrhea caused by ETEC. Impressive results obtained in a recently conducted clinical Phase I study triggered this decision. PATH supports the project by providing expertise, know-how, and financial resources.

21 Maj 2013 08:00

Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries

Travelers’ diarrhea is the leading cause of illness among international travelers to developing countries. ETEC bacteria are the primary cause of this disease. ETEC is also a major cause of diarrheal disease among children living in endemic countries. A clinical Phase I study of a novel vaccine against diarrhea caused by ETEC has been successfully completed. All primary endpoints were achieved.

21 Maj 2013 08:00

Scandinavian Biopharma rapporterar framgångsrika resultat i placebo-kontrollerad Fas I studie av ett drickbart diarrévaccin för resenärer och barn i utvecklingsländer

Turistdiarré är den vanligaste infektionssjukdomen bland resenärer till tropiska länder och orsakas oftast av toxinbildande E. coli bakterier (ETEC). ETEC orsakar även diarré bland barn i utvecklingsländer. Ett nytt drickbart ETEC vaccin har utvecklats i Sverige och en stor Fas I studie av vaccinet har nu framgångsrikt genomförts. Alla fördefinierade mål för studien har uppnåtts och överträffats.

Kategorier: path